-
公开(公告)号：US20130034731A1
公开(公告)日：2013-02-07
申请号：US13516114
申请日：2010-12-17
申请人： Shizuo Akira , Ken Ishii , Cevayir Coban , Toshihiro Tsukui , Yoshikatsu Igari , Keiichi Ohata
发明人： Shizuo Akira , Ken Ishii , Cevayir Coban , Toshihiro Tsukui , Yoshikatsu Igari , Keiichi Ohata
CPC分类号： A61K39/39 , A61K39/015 , A61K39/35 , A61K2039/543 , A61K2039/55505 , A61K2039/55511 , A61K2039/55561 , Y02A50/39 , Y02A50/407 , Y02A50/466 , Y02A50/484 , Y10T428/2982
摘要： The present invention is directed to providing a method for preparing a vaccine adjuvant composition containing β-hematin and a vaccine adjuvant composition obtained by the preparation method. The present invention is directed to a vaccine adjuvant composition containing a β-hematin crystal having an average particle size of 20 to 500 nm.
摘要翻译： 本发明涉及提供一种制备含有本发明的疫苗佐剂组合物的方法和通过该制备方法获得的疫苗佐剂组合物。 本发明涉及一种含有平均粒度为20〜500nm的白蛋白晶体的疫苗佐剂组合物。
-
公开(公告)号：US09056094B2
公开(公告)日：2015-06-16
申请号：US12740899
申请日：2008-10-31
申请人： Toshihiro Tsukui , Ken Ishii , Shizuo Akira , Cevayir Coban
发明人： Toshihiro Tsukui , Ken Ishii , Shizuo Akira , Cevayir Coban
CPC分类号： A61K39/39 , A61K9/0019 , A61K39/35 , A61K47/46 , A61K2039/55516
摘要： The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.
摘要翻译： 本发明提供了与变应原疫苗，感染疫苗或肿瘤疫苗组合使用的疫苗佐剂组合物。 本发明具体提供一种疫苗佐剂组合物，其包含血红素或重金属，并与变应原疫苗，感染疫苗或肿瘤疫苗组合使用，以及包含疫苗佐剂组合物和变应原疫苗，感染疫苗或肿瘤的疫苗组合物 疫苗。
-
公开(公告)号：US20100247568A1
公开(公告)日：2010-09-30
申请号：US12740899
申请日：2008-10-31
申请人： Toshihiro Tsukui , Ken Ishii , Shizuo Akira , Cevayir Coban
发明人： Toshihiro Tsukui , Ken Ishii , Shizuo Akira , Cevayir Coban
CPC分类号： A61K39/39 , A61K9/0019 , A61K39/35 , A61K47/46 , A61K2039/55516
摘要： The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine
摘要翻译： 本发明提供了与变应原疫苗，感染疫苗或肿瘤疫苗组合使用的疫苗佐剂组合物。 本发明具体提供一种疫苗佐剂组合物，其包含血红素或重金属，并与变应原疫苗，感染疫苗或肿瘤疫苗组合使用，以及包含疫苗佐剂组合物和变应原疫苗，感染疫苗或肿瘤的疫苗组合物 疫苗
-
公开(公告)号：US08075898B2
公开(公告)日：2011-12-13
申请号：US11547850
申请日：2005-04-07
CPC分类号： C07K14/43531 , A61K39/00 , A61K39/35 , G01N33/56905 , G01N33/6854
摘要： A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
摘要翻译： 提供安全有效的重组螨变应原作为不含过敏反应性杂质的螨过敏性疾病的治疗剂或诊断剂。 提供以下重组蛋白（a）或（b）：（a）包含SEQ ID NO：2或35所示的氨基酸序列的蛋白质; 或（b）通过缺失，取代或添加一个或几个氨基酸并具有螨变应原活性的蛋白质，其包含由SEQ ID NO：2或35所示的氨基酸序列衍生的氨基酸序列。
-
公开(公告)号：US08647630B2
公开(公告)日：2014-02-11
申请号：US13230448
申请日：2011-09-12
IPC分类号： A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC分类号： C07K14/43531 , A61K39/00 , A61K39/35 , G01N33/56905 , G01N33/6854
摘要： A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
摘要翻译： 提供安全有效的重组螨变应原作为不含过敏反应性杂质的螨过敏性疾病的治疗剂或诊断剂。 提供以下重组蛋白（a）或（b）：（a）包含SEQ ID NO：2或35所示的氨基酸序列的蛋白质; 或（b）通过缺失，取代或添加一个或几个氨基酸并具有螨变应原活性的蛋白质，其包含由SEQ ID NO：2或35所示的氨基酸序列衍生的氨基酸序列。
-
公开(公告)号：US20110091490A1
公开(公告)日：2011-04-21
申请号：US12440973
申请日：2007-09-13
CPC分类号： A61K39/12 , A61K39/175 , A61K39/235 , A61K2039/5254 , A61K2039/54 , A61K2039/542 , A61K2039/543 , A61K2039/552 , A61K2039/70 , C12N7/00 , C12N2710/10334 , C12N2710/10364 , C12N2750/14334 , C12N2750/14364 , C12N2760/18434 , C12N2760/18464
摘要： This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the attenuated canine adenovirus type 2 strain obtained by adapting the canine adenovirus type 2 F1 strain in cultured cells to attenuate the same, and an attenuated canine parvovirus strain obtained by adapting the canine parvovirus F3 strain in cultured cells to attenuate the same.
摘要翻译： 本发明提供针对犬瘟热病毒感染，犬腺病毒2型感染和可口服给予的犬细小病毒感染的疫苗。 本发明还提供了通过使培养细胞中的犬瘟热病毒95-54株适应其减毒方法获得的减毒犬瘟热病毒株，通过将培养细胞中的犬腺病毒2型F1菌株适应于减毒的犬腺病毒2型菌株 通过使犬细小病毒F3菌株在培养的细胞中适应性减弱而获得的减毒犬细小病毒株减弱。
-
公开(公告)号：US20080260759A1
公开(公告)日：2008-10-23
申请号：US11547850
申请日：2005-04-07
IPC分类号： A61K39/35 , C07K14/435 , C07K7/08 , C07K7/06 , C12N15/12 , C12N15/63 , G01N33/53 , C07K16/18 , C12N1/21 , C12N1/19 , C12N5/10 , C12P21/00
CPC分类号： C07K14/43531 , A61K39/00 , A61K39/35 , G01N33/56905 , G01N33/6854
摘要： A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
摘要翻译： 提供安全有效的重组螨变应原作为不含过敏反应性杂质的螨过敏性疾病的治疗剂或诊断剂。 提供以下重组蛋白（a）或（b）：（a）包含SEQ ID NO：2或35所示的氨基酸序列的蛋白质; 或（b）通过缺失，取代或添加一个或几个氨基酸并具有螨变应原活性的蛋白质，其包含由SEQ ID NO：2或35所示的氨基酸序列衍生的氨基酸序列。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.029 秒)